Hematoma-like primary cutaneous peripheral T-cell lymphoma: a rare clinical presentation.

Hematoma-like primary cutaneous peripheral T-cell lymphoma: a rare clinical presentation. G Ital Dermatol Venereol. 2020 Feb 13;: Authors: Mercuri SR, Paolino G, Colombo L, Bearzi P, Bellinzona F, Perrone S, Sassone M, Berti E, Rizzo N PMID: 32057216 [PubMed - as supplied by publisher]
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research

Related Links:

Conclusion: In patients with early-stage nasal NKTCL, our LVD-IMRT regimen produced excellent, durable therapeutic benefit in most patients, with acceptable toxicity and no acute mortality.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Head and Neck Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Source Type: research
Abstract Treatment outcomes in pediatric lymphoma have improved substantially over the past 2 decades; however, the prognosis for patients with high risk or relapsed disease remains poor. We evaluated outcomes of high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) in 56 pediatric lymphoma patients. Patients received nitrosourea (51 BCNU; 5 ACNU), etoposide, and cyclophosphamide (BEC; AEC). Median age at HDC/auto-SCT was 12 years (range 2-17 years). Forty-four patients underwent HDC/auto-SCT because they did not achieve complete remission after induction chemotherapy. Eight pa...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
li Zu Anaplastic large cell lymphoma (ALCL) is the most common T-cell lymphoma in children. ALCL cells characteristically express surface CD30 molecules and carry the pathogenic ALK oncogene, both of which are diagnostic biomarkers and are also potential therapeutic targets. For precision therapy, we report herein a protamine nanomedicine incorporated with oligonucleotide aptamers to selectively target lymphoma cells, a dsDNA/drug payload to efficiently kill targeted cells, and an siRNA to specifically silence ALK oncogenes. The aptamer-equipped protamine nanomedicine was simply fabricated through a non-covalent charge...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract Purpose: In the present study, we aimed to investigate whether the metabolic parameters on baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) could be used to predict prognosis in peripheral T-cell lymphomas (PTCL). Methods: A total of 51 nodal PTCL patients who underwent baseline 18F-FDG PET/CT were retrospectively evaluated in the present study. Total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximum standardized uptake value (SUVmax) were also assessed. Besides, the National Comprehensive Cancer Network International Prognostic...
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
CONCLUSION: These preliminary results indicate that further studies are needed to determine the prognostic value of TOPIIα expression with regard to the sensitivity of canine B-cell lymphomas to anthracycline-based chemotherapy regimen. Nevertheless, this study indicates the possibility of choosing the appropriate treatment of canine lymphoma based on TOPIIα expression. PMID: 32176312 [PubMed - as supplied by publisher]
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
Publication date: 16 March 2020Source: Cancer Cell, Volume 37, Issue 3Author(s): Jie Xiong, Bo-Wen Cui, Nan Wang, Yu-Ting Dai, Hao Zhang, Chao-Fu Wang, Hui-Juan Zhong, Shu Cheng, Bin-Shen Ou-Yang, Yu Hu, Xi Zhang, Bin Xu, Wen-Bin Qian, Rong Tao, Feng Yan, Jian-Da Hu, Ming Hou, Xue-Jun Ma, Xin Wang, Yuan-Hua Liu
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
More News: Dermatology | Lymphoma | Skin | T-cell Lymphoma